TD Cowen analyst Josh Jennings maintained a Buy rating on Establishment Labs Holdings (ESTA – Research Report) yesterday. The company’s shares closed last Wednesday at $47.28.
According to TipRanks, Jennings is a 5-star analyst with an average return of 8.9% and a 53.20% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and TransMedics Group.
Establishment Labs Holdings has an analyst consensus of Strong Buy, with a price target consensus of $61.40.
Based on Establishment Labs Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $40.23 million and a GAAP net loss of $16.68 million. In comparison, last year the company earned a revenue of $38.51 million and had a GAAP net loss of $29.27 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ESTA in relation to earlier this year. Last month, JW Asset Management, LLC, a Major Shareholder at ESTA sold 100,000.00 shares for a total of $4,515,000.00.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Establishment Labs Holdings (ESTA) Company Description:
Establishment Labs Holdings, Inc. engages in the design, development, manufacture, and marketing of silicone breast implants. It offers its products under Motiva Implants brand. The company was founded by Juan Jose Chacon-Quiros in 2013 and is headquartered in Alajuela, Costa Rica.
